Travere Therapeutics (TVTX) News Today $21.98 -1.60 (-6.79%) Closing price 04:00 PM EasternExtended Trading$21.97 -0.01 (-0.05%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Travere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Misses Expectations By $0.15 EPSTravere Therapeutics (NASDAQ:TVTX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%.February 21 at 4:49 PM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Misses Estimates By $0.15 EPSTravere Therapeutics (NASDAQ:TVTX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%.February 21 at 4:33 PM | marketbeat.comTravere Therapeutics price target raised to $30 from $24 at TD CowenFebruary 21 at 10:40 AM | markets.businessinsider.comTravere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call TranscriptFebruary 21 at 9:09 AM | seekingalpha.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives $27.77 Average Price Target from BrokeragesFebruary 21 at 1:47 AM | americanbankingnews.comTravere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 20 at 4:01 PM | globenewswire.comTravere Therapeutics (TVTX) Expected to Announce Quarterly Earnings on ThursdayFebruary 18 at 3:39 AM | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rFebruary 18 at 2:46 AM | marketbeat.comEntropy Technologies LP Purchases New Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,300 shares of the company's stock, valued at appFebruary 15, 2025 | marketbeat.comTravere Therapeutics price target raised to $47 from $45 at GuggenheimFebruary 14, 2025 | markets.businessinsider.comFY2026 Earnings Estimate for TVTX Issued By Leerink PartnrsFebruary 14, 2025 | americanbankingnews.comTravere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsFebruary 13, 2025 | globenewswire.comFY2026 Earnings Forecast for TVTX Issued By Leerink PartnrsTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for Travere Therapeutics in a note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz now expects that the company wiFebruary 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 SharesFebruary 13, 2025 | insidertrades.comTravere Therapeutics (TVTX) to Release Quarterly Earnings on ThursdayTravere Therapeutics (NASDAQ:TVTX) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports.February 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 SharesTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 3,074 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $76,850.00. Following the completion of the transaction, the insider now directly owns 127,634 shares in the company, valued at approximately $3,190,850. This trade represents a 2.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.February 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote Sells 5,200 SharesTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) SVP William E. Rote sold 5,200 shares of the stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the transaction, the senior vice president now directly owns 98,519 shares of the company's stock, valued at approximately $2,318,152.07. This represents a 5.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.February 13, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube Sells 11,375 SharesTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric M. Dube sold 11,375 shares of Travere Therapeutics stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total transaction of $273,455.00. Following the completion of the sale, the chief executive officer now owns 419,173 shares of the company's stock, valued at approximately $10,076,918.92. This trade represents a 2.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.February 13, 2025 | marketbeat.comSandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CAO Sandra Calvin sold 54,244 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.00. Following the sale, the chief accounting officer now directly owns 54,410 shares of the company's stock, valued at approximately $1,360,250. This trade represents a 49.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.February 13, 2025 | marketbeat.comTravere therapeutics CEO Eric M. Dube sells $273,455 in stockFebruary 12, 2025 | msn.comTravere therapeutics officer sells shares worth over $1.35 millionFebruary 12, 2025 | msn.comCanaccord raises Travere Therapeutics target to $45; Keeps BuyFebruary 12, 2025 | msn.comTravere Therapeutics price target raised to $32 from $27 at ScotiabankFebruary 12, 2025 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Buy from ScotiabankFebruary 12, 2025 | markets.businessinsider.comWhy Travere Therapeutics Inc. (TVTX) Went Up On Tuesday?February 12, 2025 | msn.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 12, 2025 | globenewswire.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $32.00Scotiabank increased their price objective on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a research report on Wednesday.February 12, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Given New $45.00 Price Target at Evercore ISIEvercore ISI upped their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday.February 12, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00Canaccord Genuity Group lifted their price target on Travere Therapeutics from $22.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday.February 12, 2025 | marketbeat.comTravere Therapeutics stock soars on FDA meeting outcomeFebruary 11, 2025 | msn.comTravere Therapeutics (NASDAQ:TVTX) Sets New 12-Month High - Here's WhyTravere Therapeutics (NASDAQ:TVTX) Sets New 12-Month High - Should You Buy?February 11, 2025 | marketbeat.comTravere Therapeutics, Inc.: Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGSFebruary 11, 2025 | finanznachrichten.deTravere Therapeutics stock rises on sNDA submission plans for FILSPARIFebruary 11, 2025 | au.investing.comTravere therapeutics director Roy Baynes sells $220,000 in stockFebruary 11, 2025 | msn.comTravere Therapeutics to submit sNDA for FILSPARI in FSGSFebruary 11, 2025 | markets.businessinsider.comWells bullish on Travere Therapeutics, sees 30% of upside on submission plansFebruary 11, 2025 | markets.businessinsider.comTravere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGSFebruary 11, 2025 | globenewswire.comRoy D. Baynes Sells 10,000 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockFebruary 11, 2025 | insidertrades.comCritical Contrast: Travere Therapeutics (NASDAQ:TVTX) vs. Vivesto (OTCMKTS:OASMY)February 11, 2025 | americanbankingnews.comInsider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells 10,000 Shares of StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) Director Roy D. Baynes sold 10,000 shares of Travere Therapeutics stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $22.00, for a total transaction of $220,000.00. Following the completion of the transaction, the director now directly owns 31,000 shares in the company, valued at $682,000. This represents a 24.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 10, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.6% - Should You Sell?Travere Therapeutics (NASDAQ:TVTX) Trading Down 4.6% - Time to Sell?February 10, 2025 | marketbeat.comabrdn plc Invests $6.83 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX)abrdn plc bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 392,000 shares of the company's stock, valued at approximately $6,829,000. abrdn plc owned about 0.50% of Travere ThFebruary 9, 2025 | marketbeat.comJennison Associates LLC Invests $14.22 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX)Jennison Associates LLC purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 816,399 shares of the company's stock, valued at approximately $14,222,000. Jennison Associates LLC owFebruary 6, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Sets New 12-Month High - Here's What HappenedTravere Therapeutics (NASDAQ:TVTX) Reaches New 52-Week High - What's Next?February 5, 2025 | marketbeat.comTravere therapeutics' chief commercial officer sells $103,939 in stockFebruary 5, 2025 | msn.comTravere therapeutics CEO Eric Dube sells $1.02 million in stockFebruary 5, 2025 | msn.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $67,361.76 in StockFebruary 5, 2025 | insidertrades.comSandra Calvin Sells 3,348 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CAO Sandra Calvin sold 3,348 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $67,361.76. Following the completion of the transaction, the chief accounting officer now owns 63,654 shares in the company, valued at approximately $1,280,718.48. This represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.February 4, 2025 | marketbeat.comJula Inrig Sells 4,207 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 4,207 shares of Travere Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total value of $84,644.84. Following the completion of the transaction, the insider now directly owns 85,236 shares in the company, valued at $1,714,948.32. This represents a 4.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.February 4, 2025 | marketbeat.comInsider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Sells 5,192 Shares of StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher R. Cline sold 5,192 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $104,463.04. Following the transaction, the chief financial officer now owns 90,038 shares of the company's stock, valued at approximately $1,811,564.56. The trade was a 5.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.February 4, 2025 | marketbeat.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼0.060.60▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼136▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News Today Legend Biotech News Today BridgeBio Pharma News Today Axsome Therapeutics News Today Blueprint Medicines News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Elanco Animal Health News Today Lantheus News Today Nuvalent News Today Cytokinetics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVTX Stock Alerts